期刊
EUROPEAN RESPIRATORY JOURNAL
卷 38, 期 1, 页码 36-41出版社
EUROPEAN RESPIRATORY SOC JOURNALS LTD
DOI: 10.1183/09031936.00077010
关键词
Chronic obstructive pulmonary disease; community-acquired pneumonia; inhaled corticosteroids; outcome
资金
- Medical Research Council (London, UK)
The aim of this study was to investigate whether inhaled corticosteroid (ICS) use affects outcome in patients with chronic obstructive pulmonary disease (COPD) admitted with community-acquired pneumonia (CAP). This was a prospective, observational study of patients with spirometry-confirmed COPD presenting with a primary diagnosis of CAP in Lothian, UK. Outcome measures were compared between ICS users and non-ICS users. Of 490 patients included in the study, 76.7% were classified as ICS users. ICS users had higher Global Initiative for Chronic Obstructive Lung Disease (GOLD) stage compared with non-ICS users (mean +/- SD 3.2 +/- 0.8 versus 2.6 +/- 0.9; p<0.0001). There were no significant differences in pneumonia severity (mean +/- SD Pneumonia Severity Index (PSI) 4.2 +/- 0.8 versus 4.3 +/- 0.8 (p=0.3); mean +/- SD CURB-65 score 2.1 +/- 1.3 versus 2.3 +/- 1.3 (p=0.07)) or markers of systemic inflammation (median C-reactive protein 148 (interquartile range 58-268) mg.L(-1) versus 183 (IQR 85-302) mg.L(-1); p=0.08) between ICS users and non-ICS users. On multivariable analysis, after adjustment for COPD severity and PSI, ICS use was not independently associated with 30-day mortality (OR 1.71, 95% CI 0.75-3.90; p=0.2), 6-month mortality (OR 1.62, 95% CI 0.82-3.16; p=0.2), requirement for mechanical ventilation and/or inotropic support (OR 0.73, 95% CI 0.33-1.62; p=0.4) or development of complicated pneumonia (OR 0.71, 95% CI 0.25-1.99; p=0.5). Prior ICS use had no impact on outcome in patients with COPD admitted with CAP.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据